Abstract
Our data suggest that TGF-beta may attenuate the deleterious events that occur in inflammation by preventing cytokine-induced extracellular matrix degradation, although it does not affect cytokine-induced recruitment of pro-inflammatory cells. Furthermore, our data suggest a potential therapeutic use for jun-B, which may be a candidate for gene therapy in disease states that are characterized by excessive connective tissue degradation.